Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR6 | P51684 | 1/20 | 0.57 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TGM2 | P21980 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.45 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.45 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.45 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10058216 | 0.99 | CCR6 (0.58) | CCR6PAX8HTTLMNASMN1; SMN2 | |
| SCHEMBL416889 | 0.98 | CCR6 (0.54) | CCR6PAX8HTTLMNASMN1; SMN2 | |
| SCHEMBL415502 | 0.97 | CCR6 (0.55) | CCR6PAX8HTTLMNASMN1; SMN2 | |
| SCHEMBL9773971 | 0.90 | CCR6 (0.58) | CCR6PAX8HTTLMNASMN1; SMN2 | |
| SCHEMBL10025426 | 0.90 | CCR6 (0.60) | CCR6PAX8HTTLMNASMN1; SMN2 | |
| SCHEMBL10025433 | 0.89 | CCR6 (0.61) | CCR6PAX8HTTLMNASMN1; SMN2 | |
| SCHEMBL415507 | 0.88 | CCR6 (0.61) | CCR6PAX8HTTLMNASMN1; SMN2 | |
| SCHEMBL413839 | 0.88 | CCR6 (0.62) | CCR6PAX8HTTLMNASMN1; SMN2 | |
| SCHEMBL414180 | 0.88 | CCR6 (0.60) | CCR6PAX8HTTLMNASMN1; SMN2 | |
| SCHEMBL415194 | 0.88 | CCR6 (0.60) | CCR6PAX8HTTLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8664409-B2 | Process for the preparation of (poly) aminoalkylaminoacetamide derivatives of epipodophyllotoxin useful for their applications in therapeutics as anticancer agent | PIERRE FABRE MEDICAMENT (FR) | 2014-03-04 | — | — | US | disclosed |
| US-8664409-B2 | Process for the preparation of (poly) aminoalkylaminoacetamide derivatives of epipodophyllotoxin useful for their applications in therapeutics as anticancer agent | PIERRE FABRE MEDICAMENT (FR) | 2014-03-04 | — | — | US | disclosed |
| US-20120022273-A1 | PROCESS FOR THE PREPARATION OF (POLY) AMINOALKYLAMINOACETAMIDE DERIVATIVES OF EPIPODOPHYLLOTOXIN USEFUL FOR THEIR APPLICATIONS IN THERAPEUTICS AS ANTICANCER AGENT | PIERRE FABRE MEDICAMENT (FR) | 2012-01-26 | — | — | US | disclosed |
| US-20120022273-A1 | PROCESS FOR THE PREPARATION OF (POLY) AMINOALKYLAMINOACETAMIDE DERIVATIVES OF EPIPODOPHYLLOTOXIN USEFUL FOR THEIR APPLICATIONS IN THERAPEUTICS AS ANTICANCER AGENT | PIERRE FABRE MEDICAMENT (FR) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022273-A1 | PROCESS FOR THE PREPARATION OF (POLY) AMINOALKYLAMINOACETAMIDE DERIVATIVES OF EPIPODOPHYLLOTOXIN USEFUL FOR THEIR APPLICATIONS IN THERAPEUTICS AS ANTICANCER AGENT | PTMA, NPEPPS, DNPEP | CCR6 3824/4885PAX8 2180/4885HTT 2168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.